Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Liabilities: 2020-2025

Historic Total Liabilities for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to $294.6 million.

  • Foghorn Therapeutics' Total Liabilities fell 12.49% to $294.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $294.6 million, marking a year-over-year decrease of 12.49%. This contributed to the annual value of $329.5 million for FY2024, which is 9.25% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Total Liabilities of $294.6 million as of Q3 2025, which was down 2.73% from $302.9 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Total Liabilities peaked at $422.9 million during Q4 2021, and registered a low of $104.3 million during Q2 2021.
  • Over the past 3 years, Foghorn Therapeutics' median Total Liabilities value was $342.9 million (recorded in 2024), while the average stood at $345.4 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' Total Liabilities soared by 297.15% in 2022, and later fell by 12.49% in 2025.
  • Over the past 5 years, Foghorn Therapeutics' Total Liabilities (Quarterly) stood at $422.9 million in 2021, then dropped by 4.29% to $404.8 million in 2022, then declined by 10.29% to $363.1 million in 2023, then fell by 9.25% to $329.5 million in 2024, then declined by 12.49% to $294.6 million in 2025.
  • Its Total Liabilities was $294.6 million in Q3 2025, compared to $302.9 million in Q2 2025 and $320.3 million in Q1 2025.